#USA #New York #Levi & Korsinsky #Boston Scientific #BSX

Boston Scientific Faces Legal Challenges Amid Declining Market Growth

Boston Scientific Corporation (NYSE: BSX) is facing significant legal scrutiny as the company deals with allegations of securities fraud. This follows a noticeable decline in their stock value and reported growth figures that contradicted previous optimistic projections.

The firm Levi & Korsinsky, LLP has called upon investors who experienced losses to join a potential class-action lawsuit. Investors who purchased BSX securities between July 23, 2025, and February 3, 2026, may have a chance to recover damages as a result of the firm’s alleged misleading statements regarding their electrophysiology (EP) segment growth.

Background of the Allegations

On February 4, 2026, Boston Scientific's stock plummeted by 17.6%, closing at $75.50 per share. This sharp decline followed the company's announcement that its EP market growth was underwhelming compared to earlier forecasts. Contrary to the company's prior optimistic outlook, slower growth and heightened competition were cited as key factors for these disappointing results.

In July 2025, Boston Scientific reported a remarkable 94% sales growth in their EP segment and raised their full-year guidance to forecast overall revenue growth of 18% to 19%. During the following earnings calls, management expressed confidence in the continued growth of its EP products, asserting a sustainable and robust market.

However, as alleged in the class-action complaint, these projections were made while Boston Scientific executives were purportedly aware that the pace of growth in the EP segment was not sustainable. The situation escalated in September 2025, when the company presented a long-range plan claiming 15% EP market growth, which they declared would outpace competition.

Timeline of Events

The saga of alleged misleading information spans several critical announcements:

• - July 23, 2025: Management raised the guidance for full-year revenue growth to 18%-19% while highlighting a significant growth in EP sales.
• - September 30, 2025: During an investor conference, the company projected ambitious EP market figures, asserting it was insulated from competitive threats.
• - October 22, 2025: A subsequent guidance raise brought the full-year growth estimate to approximately 20% alongside elevated earnings per share (EPS) forecasts.
• - February 4, 2026: The company made a startling revelation regarding U.S. EP sales growth that fell short of analysts' expectations, leading to a massive drop in stock value.

Each of these announcements created a widening gap between the public optimism shared by the company and the alleged internal realities of rolling market challenges, leading to the current class action lawsuit.

Legal Implications

Joseph E. Levi, Esq., representing the firm filing the suit, emphasizes the importance of timely and truthful disclosures in maintaining fair and efficient markets. The actions of Boston Scientific have raised significant questions regarding the motivations behind their inflated growth forecasts, given the imminent challenges in the marketplace.

Shareholders considering participation in the lawsuit must act quickly, as the deadline for applying to be a lead plaintiff is set for May 4, 2026. Those interested in pursuing claims against Boston Scientific should contact Levi & Korsinsky to discuss their eligibility and potential next steps.

Conclusion

The situation unfolding at Boston Scientific serves as a reminder of the essential balance that corporations must maintain between shareholder communication and market realities. As this case develops, it will be crucial to observe how it impacts not only Boston Scientific but also the wider healthcare and investment communities as they react to ongoing legal scrutiny and changing market conditions.